Phoenix Children's Grand Rounds 2025

Return-to-Play for Athletes with SCD-Predisposing Genetic Heart Diseases: Who Says That They Can't Play Anyway? - 3/18/2025

March 18, 2025 – 7:30 AM

Other

Overall Activity Objectives:

- 1 Implement appropriate strategies for diagnosing pediatric conditions.
- 2 Evaluate and implement appropriate, current treatment options vis a vis emerging therapeutics.
- 3 Implement in practice developing areas of research and evidence-based recommendations within a diverse range of pediatric specialties.

Session Objectives:

- 1 To ASSESS the past and present expert opinion guidelines regarding competitive sports participation for patients with a sudden cardiac death (SCD)-predisposing genetic heart disease (GHD)
- 2 To EXAMINE the data that is compelling the slow evolution from disqualifying to shared decision making (SDM)

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Arizona College of Medicine - Tucson and Phoenix Children's The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)* $^{\text{TM}}$. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Relevant Financial Relationships Statement(s):

University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
John R Hartley, DO, FAAP	Activity Director	Nothing to disclose - 10/30/2024
Michael J Ackerman, MD, PhD	Faculty	Paid consultant-Boston Scientific Corporation Paid consultant-Bristol- Myers Squibb Company (Relationship has ended) Paid consultant-Invitae Corporation (Relationship has ended) Paid consultant-Medtronic (Any division) Paid consultant-Tenaya Therapeutics Royalties or Patent

Beneficiary-AliveCor Royalties or
Patent Beneficiary-ARMGO Pharma
(Relationship has ended) Royalties or
Patent Beneficiary-Prolaio Royalties or
Patent Beneficiary-Solid
Biosciences Royalties or Patent
Beneficiary-Thryv
Therapeutics Royalties or Patent
Beneficiary-UpToDate - 01/06/2025

